Tyra Biosciences closed at $21.52 on Nov 4, up 0.73%, 45.7% below its 52-week closing high. Volume of 542.9K shares was 0.92× its 20-day average (close to normal).
Split-adjusted performance: +6.3% over one month, -36.3% over six months, +39.5% over one year.
Short interest was 9.5M shares at the Oct 15 settlement (26.5% of float, 15.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| TYRATyra Biosciences | $21.53 | +0.73% | −36.3% | — | — | — | $1.48B | |
| RAPPRapport Therapeutics | $25.93 | +1.93% | −30.0% | — | — | — | $1.46B | Compare |
| MLYSMineralys Therapeutics | $17.00 | +6.32% | −43.6% | — | — | — | $1.50B | Compare |
| KARDKardigan | $15.56 | +8.66% | — | — | — | — | $1.45B | Compare |
| PCRXPacira BioSciences | $36.40 | +0.03% | +53.7% | +6.2% | 2.4% | 99.2 | $1.45B | Compare |
| ETONEton Pharmaceutcials | $50.72 | −0.45% | +68.2% | +98.6% | 30.8% | 114.3 | $1.45B | Compare |
| INVAInnoviva | $21.26 | +1.58% | −5.6% | +19.3% | −69.8% | 4.3 | $1.54B | Compare |
| ANABAnaptysBio | $47.51 | −0.46% | −29.5% | −8.0% | −206.9% | — | $1.42B | Compare |
| DMRADamora Therapeutics | $22.94 | +3.89% | — | — | — | — | $1.42B | Compare |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
